These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32687221)

  • 1. Strategies for high-concentration drug substance manufacturing to facilitate subcutaneous administration: A review.
    Holstein M; Hung J; Feroz H; Ranjan S; Du C; Ghose S; Li ZJ
    Biotechnol Bioeng; 2020 Nov; 117(11):3591-3606. PubMed ID: 32687221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mechanistic model to account for the Donnan and volume exclusion effects in ultrafiltration/diafiltration process of protein formulations.
    Yu Z; Moomaw JF; Thyagarajapuram NR; Geng SB; Bent CJ; Tang Y
    Biotechnol Prog; 2021 Mar; 37(2):e3106. PubMed ID: 33289341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Small-Scale Process for Predicting Donnan and Volume Exclusion Effects During Ultrafiltration/Diafiltration Process Development.
    Abel J; Kosky A; Ball N; Bacon H; Kaushik R; Kleemann GR
    J Pharm Sci; 2018 May; 107(5):1296-1303. PubMed ID: 29339134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-criteria manufacturability indices for ranking high-concentration monoclonal antibody formulations.
    Yang Y; Velayudhan A; Thornhill NF; Farid SS
    Biotechnol Bioeng; 2017 Sep; 114(9):2043-2056. PubMed ID: 28464235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic model of pH and excipient concentration during ultrafiltration and diafiltration processes of therapeutic antibodies.
    Ladwig JE; Zhu X; Rolandi P; Hart R; Robinson J; Rydholm A
    Biotechnol Prog; 2020 Sep; 36(5):e2993. PubMed ID: 32185869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrafiltration behavior of monoclonal antibodies and Fc-fusion proteins: Effects of physical properties.
    Baek Y; Singh N; Arunkumar A; Borys M; Li ZJ; Zydney AL
    Biotechnol Bioeng; 2017 Sep; 114(9):2057-2065. PubMed ID: 28464237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting Formulation Conditions During Ultrafiltration and Dilution to Drug Substance Using a Donnan Model with Homology-Model Based Protein Charge.
    Kannan A; Chinn M; Izadi S; Maier A; Dvornicky J; Fedesco M; Day E; Ladiwala A; Woys A
    J Pharm Sci; 2023 Mar; 112(3):820-829. PubMed ID: 36336103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Near Infrared Spectroscopy as a PAT tool for monitoring and control of protein and excipient concentration in ultrafiltration of highly concentrated antibody formulations.
    Thakur G; Hebbi V; Rathore AS
    Int J Pharm; 2021 May; 600():120456. PubMed ID: 33711473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Theoretical analysis of excipient concentrations during the final ultrafiltration/diafiltration step of therapeutic antibody.
    Miao F; Velayudhan A; DiBella E; Shervin J; Felo M; Teeters M; Alred P
    Biotechnol Prog; 2009; 25(4):964-72. PubMed ID: 19569193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Process analytical technology for on-line monitoring of quality attributes during single-use ultrafiltration/diafiltration.
    West JM; Feroz H; Xu X; Puri N; Holstein M; Ghose S; Ding J; Li ZJ
    Biotechnol Bioeng; 2021 Jun; 118(6):2293-2300. PubMed ID: 33666234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High concentration biotherapeutic formulation and ultrafiltration: Part 1 pressure limits.
    Lutz H; Arias J; Zou Y
    Biotechnol Prog; 2017 Jan; 33(1):113-124. PubMed ID: 27452237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Streamlining process characterization efforts using the high throughput ambr® crossflow system for ultrafiltration and diafiltration processing of monoclonal antibodies.
    Fernandez-Cerezo L; Benner SW; Pollard JM
    Biotechnol Prog; 2021 May; 37(3):e3118. PubMed ID: 33369289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting diafiltration solution compositions for final ultrafiltration/diafiltration steps of monoclonal antibodies.
    Teeters M; Bezila D; Benner T; Alfonso P; Alred P
    Biotechnol Bioeng; 2011 Jun; 108(6):1338-46. PubMed ID: 21328314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing scalable ultrafiltration/diafiltration process of monoclonal antibodies via mathematical modeling by coupling mass balances and Poisson-Boltzmann equation.
    Ambrožič R; Arzenšek D; Podgornik A
    Biotechnol Bioeng; 2021 Feb; 118(2):633-646. PubMed ID: 33049074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Excipient Effects on Reversible Self-Association, Backbone Flexibility, and Solution Properties of an IgG1 Monoclonal Antibody at High Concentrations: Part 1.
    Hu Y; Arora J; Joshi SB; Esfandiary R; Middaugh CR; Weis DD; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):340-352. PubMed ID: 31201906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developability Assessments of Monoclonal Antibody Candidates to Minimize Aggregation During Large-Scale Ultrafiltration and Diafiltration (UF-DF) Processing.
    Whitaker N; Pace SE; Merritt K; Tadros M; Khossravi M; Deshmukh S; Cheng Y; Joshi SB; Volkin DB; Dhar P
    J Pharm Sci; 2022 Nov; 111(11):2998-3008. PubMed ID: 35940242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Impurities from Sugar Excipient on Filtrate Flux during Ultrafiltration and Diafiltration Process.
    Lee J; Na J; Baek Y
    Membranes (Basel); 2021 Oct; 11(10):. PubMed ID: 34677543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation of milk protein concentrates by ultrafiltration and continuous diafiltration: Effect of process design on overall efficiency.
    Gavazzi-April C; Benoit S; Doyen A; Britten M; Pouliot Y
    J Dairy Sci; 2018 Nov; 101(11):9670-9679. PubMed ID: 30172402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Process Analytical Technology (PAT) Implementation for Membrane Operations in Continuous Manufacturing of mAbs: Model-Based Control of Single-Pass Tangential Flow Ultrafiltration.
    Thakur G; Masampally V; Kulkarni A; Rathore AS
    AAPS J; 2022 Jul; 24(4):83. PubMed ID: 35831532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of ultrafiltration/diafiltration for the processing of antisense oligonucleotides.
    Gronke RS; Ruanjaikaen K; Delavari A; Immel-Brown JP; Penrod JC; Lam Y; Antia FD
    Biotechnol Prog; 2023; 39(4):e3350. PubMed ID: 37186510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.